Table 2.
Main characteristics of enrolled patients.
| Trialreference | Arm (accrual period) | No. pts | Age, yr, median | ECOG PS 0, 1, 2 (%) | PD-L1 NE (%) | PD-L1a neg, low, high (%) |
|---|---|---|---|---|---|---|
| KN-189 (1) | Pembro-Combo vs. Placebo-Combo (02/2016-03/2017) |
410 206 |
65 63.5 |
45, 54, 0.2 39, 61, 0 |
6 7 |
31, 31, 32 31, 28, 34 |
| KN-021 (2, 11) | Pembro-Chemo vs. Chemo (11/2014-01/2016) |
60 63 |
62.5 63 |
40, 58, 0 46, 54, 0 |
0 0 |
35, 32, 33 37, 37, 27 |
| KN-4074 | Pembro-Chemo vs. Placebo-Chemo (NR) |
278 281 |
65 65 |
26, 74, 0 32, 68, 0 |
2.5 2 |
34, 37, 26 35, 37, 26 |
| IMPower131 (5) | Atezo-Chemo vs. Chemo (NR) |
343 340 |
65 65 |
34, 66, 0 32, 68, 0 |
0.3 0 |
47, 38, 15 50, 36, 14 |
| IMPower150 (6) | Atezo-Chemo-Beva vs. Chemo-Beva (03/2015-12/2016) |
400 400 |
63 63 |
40, 60, 0 45, 55, 0 |
0 0 |
48, 33, 19 51, 31, 18 |
| IMPower150bis (7) | Atezo-Chemo vs. Chemo-Beva (03/2015-12/2016) |
402 400 |
63 63 |
45, 55, 0 45, 55, 0 |
0.2 0 |
47, 36, 17 51, 31, 18 |
| IMPower132 (8) | Atezo-Chemo Placebo-Chemo (NR) |
292 286 |
64 63 |
43, 57, 0 40, 60,0 |
NR NR |
NR NR |
| IMPower130 (9) | Atezo-Chemo Placebo-Chemo (NR) |
451 228 |
NR NR |
58, 42, 0 60, 40, 0 |
0 0 |
52, 28, 20 53, 29, 18 |
| CM-227 (10)b | Nivo-Chemo vs. Chemo (NR) |
177 186 |
64 64 |
33, 66, NR 31, 68, NR |
NA NA |
100, 0, 0 100, 0, 0 |
Atezo, atezolizumab; Beva, bevacizumab; Carbo, carboplatin; Chemo, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IC, tumor-infiltrating immune cell; ICPIs, immune-checkpoint inhibitors; NA, not applicable; NE, not evaluated; neg, negative; NR, not reported; Nivo, nivolumab; Pembro, pembrolizumab; vs, versus; TC, tumor cell.
a
For Pembro, negative = <1%, low = 1-49%, high ≥ 50% by the use of the 22C3 pharmDx assay (Agilent); for Atezo, negative = TC0 and IC0; low = TC 1/2 or IC 1/2; high = TC3 or IC3 by the use of the SP142 PD-L1 immunohistochemistry assay (Ventana Medical Systems).
b
Study results restricted to patients with <1% PD-L1 expression.